BEAM — Beam Therapeutics Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1745999 ·
Last close
$20.65
Market Cap
$2.14B
52W High
$38.26
52W Low
$20.23
ADV30
2,017,283
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 307,000 — -141,322,000 -134,405,000 1,269,072,000 213,267,000 316,398,000
Jun 2026 490,000 — -126,553,000 -122,678,000 1,386,355,000 219,825,000 318,913,000
Mar 2026 31,738,000 — -107,215,000 -94,318,000 1,480,798,000 288,291,000 316,360,000
Dec 2025 114,109,000 — -17,445,000 244,297,000 1,481,177,000 294,944,000 242,819,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-388,646,000
Investing CF
$225,658,000
Financing CF
$108,344,000
CapEx
$-9,591,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,992,620,000
Inventory
—
Receivables
—
ST Investments
$830,606,000
EBIT TTM
$-392,535,000
Pretax Income TTM
$-107,559,000
Interest Exp TTM
—
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$146,644,000
EBITDA
$-370,407,008
Free Cash Flow
$-262,630,256
Enterprise Value
$1,832,278,400
Total Cash
$1,043,873,024
Total Debt
$243,872,000
Shares Out
103,495,644
Trailing EPS
$-0.87
Book Value
$9.56
ROE
-11.3%
ROA
-19.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 139,743,000 -383,693,000 -79,992,000 1,481,177,000 242,819,000 1,238,358,000 -345,102,000
Dec 2024 63,518,000 -415,568,000 -376,742,000 1,103,824,000 370,279,000 733,545,000 -347,246,000
Dec 2023 377,709,000 -176,485,000 -132,527,000 1,459,714,000 478,385,000 981,329,000 -149,195,000
Dec 2022 60,920,000 -338,479,000 -289,088,000 1,341,714,000 608,240,000 733,474,000 22,527,000

TTM Snapshot

Revenues TTM
$156,035,000
NetIncome TTM
$-85,427,000
OpCashFlow TTM
—
Assets (Latest)
$1,386,355,000
Forward EPS
$-4.98

Max Pain — expiry 2028-01-21

max pain strike: $22.00 · spot: $21.01 · call oi: 4,676 · put oi: 927
Expected Move to 2028-01-21: ±$12.65 (60.21%) — implied range $8.36 – $33.66 · ATM straddle on $22.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BCRX BIOCRYST PHARMACEUTICALS INC $1.93B $7.50 —
REPL Replimune Group, Inc. $1.87B $19.69 —
COAG Hemab Therapeutics Holdings, Inc. $1.83B $39.06 —
MAZE Maze Therapeutics, Inc. $1.80B $32.87 —
RXRX RECURSION PHARMACEUTICALS, INC. $1.69B $2.72 —

News headlines (Yahoo Finance, 1h cache)

Positive Trial Results Could Be A Big Moment For Beam Therapeutics (BEAM)
2026-11-18 23:21 · Yahoo
Beam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A Test
2026-11-11 00:16 · Yahoo
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
2026-11-10 17:06 · Yahoo
Beam Therapeutics to seek approval of SCD cell therapy after trial success
2026-11-10 17:05 · Yahoo
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
2026-11-10 12:00 · Yahoo
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
2026-11-04 14:00 · Yahoo
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
2026-11-03 12:15 · Yahoo
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
2026-11-03 12:00 · Yahoo
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
2026-10-29 15:30 · Yahoo
Why Beam Therapeutics Stock Is Up 15.6% And What's Next
2026-10-29 10:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.